These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 26668321)

  • 1. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
    Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
    J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
    Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
    Serrano-Marco L; Barroso E; El Kochairi I; Palomer X; Michalik L; Wahli W; Vázquez-Carrera M
    Diabetologia; 2012 Mar; 55(3):743-51. PubMed ID: 22179221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
    Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
    Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
    Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.
    Costet P; Cariou B; Lambert G; Lalanne F; Lardeux B; Jarnoux AL; Grefhorst A; Staels B; Krempf M
    J Biol Chem; 2006 Mar; 281(10):6211-8. PubMed ID: 16407292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.
    Jeong HJ; Lee HS; Kim KS; Kim YK; Yoon D; Park SW
    J Lipid Res; 2008 Feb; 49(2):399-409. PubMed ID: 17921436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
    Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.
    Dong B; Li H; Singh AB; Cao A; Liu J
    J Biol Chem; 2015 Feb; 290(7):4047-58. PubMed ID: 25540198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
    Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
    J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells.
    Cao A; Wu M; Li H; Liu J
    J Lipid Res; 2011 Mar; 52(3):518-30. PubMed ID: 21196532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells.
    Xiang S; Dong NG; Liu JP; Wang Y; Shi JW; Wei ZJ; Hu XJ; Gong L
    J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):615-622. PubMed ID: 24142708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells.
    Wiejak J; Dunlop J; Mackay SP; Yarwood SJ
    Biochem J; 2013 Sep; 454(2):283-93. PubMed ID: 23782265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3.
    Macchi C; Greco MF; Botta M; Sperandeo P; Dongiovanni P; Valenti L; Cicero AFG; Borghi C; Lupo MG; Romeo S; Corsini A; Magni P; Ferri N; Ruscica M
    Am J Pathol; 2020 Nov; 190(11):2226-2236. PubMed ID: 32798443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.